← Back to Screener
Artelo Biosciences, Inc. Common Stock (ARTL)
Price$4.53
Favorite Metrics
Price vs S&P 500 (26W)-75.93%
Price vs S&P 500 (4W)-53.78%
Market Capitalization$3.96M
All Metrics
Book Value / Share (Quarterly)$1.19
P/TBV (Annual)4.18x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-13.03
Price vs S&P 500 (YTD)17.17%
EPS (TTM)$-39.25
10-Day Avg Trading Volume0.45M
EPS Excl Extra (TTM)$-39.25
EPS (Annual)$-37.55
ROI (Annual)-343.93%
Cash / Share (Quarterly)$0.89
ROA (Last FY)-459.80%
EBITD / Share (TTM)$-30.16
ROE (5Y Avg)-131.38%
Cash Flow / Share (Annual)$-13.03
P/B Ratio6.08x
P/B Ratio (Quarterly)4.40x
Net Income / Employee (Annual)$-2
Net Interest Coverage (TTM)-49.51x
ROA (TTM)-344.82%
EPS Incl Extra (Annual)$-37.55
Current Ratio (Annual)0.17x
Quick Ratio (Quarterly)0.15x
3-Month Avg Trading Volume1.97M
52-Week Price Return-74.57%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$1.50
52-Week High$85.80
EPS Excl Extra (Annual)$-37.55
Tangible BV CAGR (5Y)-14.97%
26-Week Price Return-67.18%
Quick Ratio (Annual)0.15x
13-Week Price Return-8.07%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)0.17x
Enterprise Value$3.972
Book Value / Share Growth (5Y)5.92%
Revenue / Employee (Annual)$0
Cash / Share (Annual)$0.89
3-Month Return Std Dev487.65%
Net Income / Employee (TTM)$-2
ROE (Last FY)-343.93%
Net Interest Coverage (Annual)-39.10x
EPS Basic Excl Extra (Annual)$-37.55
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-39.25
ROI (TTM)-226.26%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$4.49
Price vs S&P 500 (52W)-109.67%
Year-to-Date Return21.31%
5-Day Price Return-21.69%
EPS Normalized (Annual)$-37.55
ROA (5Y Avg)-169.68%
Month-to-Date Return-41.42%
Cash Flow / Share (TTM)$-3.33
EBITD / Share (Annual)$-36.80
ROI (5Y Avg)-131.38%
EPS Basic Excl Extra (TTM)$-39.25
P/TBV (Quarterly)4.18x
P/B Ratio (Annual)1.20x
Book Value / Share (Annual)$15.67
Price vs S&P 500 (13W)-10.94%
Beta0.16x
Revenue / Share (TTM)$0.00
ROE (TTM)-226.26%
52-Week Low$2.96
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
2.17
2.17
2.17
2.17
Industry Peers — Pharmaceuticals(309)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
ARTLArtelo Biosciences, Inc. Common Stock | — | — | — | — | $4.53 |
LLYEli Lilly & Co. | 13.45x | 44.70% | 83.04% | 27.59% | $919.90 |
JNJJohnson & Johnson | 5.82x | 7.87% | 67.95% | 14.90% | $230.69 |
ABBVABBVIE INC. | 5.97x | 8.57% | 71.62% | -2.88% | $203.71 |
MRKMerck & Co., Inc. | 4.51x | 1.31% | 78.55% | 21.23% | $117.10 |
AZNAstraZeneca PLC | 5.39x | 8.63% | 81.31% | 21.88% | $200.69 |
NVSNovartis AG | 4.87x | 8.91% | 75.82% | 15.26% | $150.99 |
NVONovo-Nordisk A/S | 3.74x | 6.43% | 80.98% | 20.66% | $40.46 |
ABTAbbott Laboratories | 3.71x | 6.59% | 56.50% | 8.20% | $96.00 |
PFEPfizer Inc. | 2.50x | -1.64% | 75.81% | -3.51% | $27.52 |
BMYBristol-Myers Squibb Co. | 2.52x | -0.22% | 72.63% | — | $59.13 |
About
Artelo Biosciences is a clinical-stage biopharmaceutical company developing therapies targeting the endocannabinoid system, a lipid signaling pathway involved in various diseases. The company is advancing a proprietary pipeline of cannabinoid-based therapeutics derived from cannabis plants, synthetic sources, and novel chemical entities. Its flagship program is a patent-protected cannabinoid combination treatment for rare and orphan diseases.